The specter of generic competition has long loomed over copyright’s famous drug, PDE5 Inhibitor, sparking questions about the prospects of connected pharmaceutical ventures. While initial years saw substantial returns, the patent end has created the door for less expensive alternatives, potentially reducing revenue and posing a genuine risk for i